{"id":516991,"date":"2021-07-23T07:33:13","date_gmt":"2021-07-23T11:33:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/"},"modified":"2021-07-23T07:33:13","modified_gmt":"2021-07-23T11:33:13","slug":"abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/","title":{"rendered":"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa"},"content":{"rendered":"
\n

NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL\u2122 study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa (RDEB) at UMass Memorial Medical Center in Worcester, MA.<\/p>\n

The EB-101 pivotal VIITAL\u2122 study is currently ongoing at Stanford University Medical Center in Palo Alto, CA. Target enrollment is 10 to 15 RDEB patients with approximately 35 large, chronic wound sites to be treated in total. Treatment with EB-101 uses gene transfer to deliver a functional COL7A1 gene into a patient\u2019s own skin cells (keratinocytes and its progenitors) and transplanting those cells back to the patient. EB-101 is believed to facilitate wound healing by supplementing Type VII collagen expression in RDEB patients who lack a fully functional COL7A1 gene. The co-primary endpoints of the study are: 1) the proportion of RDEB wound sites with greater than or equal to 50% healing from baseline, comparing treated with untreated wound sites at Week 24 (Month 6), as determined by direct investigator assessment; and 2) pain reduction associated with wound dressing change assessed by the mean differences in scores of the Wong-Baker FACES scale between treated and untreated wounds at Week 24 (Month 6).<\/p>\n

\u201cWe are very pleased to have UMass Memorial Medical Center as one of our VIITAL\u2122 study sites and look forward to collaborating with Dr. Karen Wiss, Director of Pediatric Dermatology at UMass Memorial to screen and enroll subjects as soon as possible,” said Vishwas Seshadri, Ph.D., M.B.A., Head of Research & Clinical Development of Abeona. \u201cWith UMass and Stanford, we are able to provide convenient treatment locations on the East Coast and West Coast to make travel and logistics easier for patients and families, while also expanding physician experience with EB-101 as we plan for potential commercial launch.\u201d<\/p>\n

\u201cWe are excited to participate in the EB-101 VIITAL\u2122 study and to offer this potentially promising investigational therapy to RDEB patients who currently have no adequate treatment options. We look forward to participating in the Phase 3 trial to evaluate the efficacy and safety of this investigational treatment,\u201d said Karen Wiss, M.D., FAAD, Professor of Dermatology and Pediatrics at UMass Medical School and Principal Investigator of the study at UMass Memorial Medical Center.<\/p>\n

\n About Recessive Dystrophic Epidermolysis Bullosa <\/strong>
\n
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. People with RDEB have a defect in the COL7A1 gene, leaving them unable to produce functioning type VII collagen, which is necessary to anchor the dermal and epidermal layers of the skin. There is currently no approved treatment for RDEB.<\/p>\n

\n About EB-101<\/strong>
\n
EB-101 is an autologous, gene-corrected cell therapy currently being investigated in Abeona\u2019s pivotal Phase 3 VIITAL\u2122 study for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder without an approved therapy. The EB-101 VIITAL\u2122 study is a randomized clinical trial enrolling 10 to 15 RDEB patients with approximately 35 large, chronic wound sites treated in total. Treatment with EB-101 involves using gene transfer to deliver the COL7A1 gene into a patient\u2019s own skin cells (keratinocytes and its progenitors) and transplanting those cells back to the patient. EB-101 is believed to enable normal Type VII collagen expression and facilitate wound healing. Abeona produces EB-101 for the VIITAL\u2122 study at its fully integrated gene and cell therapy manufacturing facility in Cleveland, OH.<\/p>\n

In a Phase 1\/2a clinical trial of EB-101, participants with RDEB were \u226518 years old, had two COL7A1 genetic mutations and chronic open wounds \u2265 20 cm2, for \u2265 12 weeks. Autologous keratinocytes were cultured from biopsies of intact skin and transduced with a retrovirus containing full-length COL7A1 to form gene-corrected epidermal sheets (EB-101) measuring 35 cm2. EB-101 was transplanted onto 38 chronic wound sites in 7 participants from 2013 to 2017. Investigator assessment of wound healing and pain assessment from last available visit was recorded, followed by a survey 3 to 6 years after treatment asking participants to rate change in pain compared with their pre-treatment state using a seven-point scale, ranging from 1 (very much improved) to 7 (very much worse). EB-101 is an investigational product not yet approved by the FDA.<\/p>\n

\n About Abeona Therapeutics <\/strong>
\n
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona\u2019s clinical programs include EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel investigational AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1\/2 development. The Company\u2019s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona\u2019s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona\u2019s fully integrated gene and cell therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL\u2122 study and is capable of clinical and planned commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
\n This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as \u201cmay,\u201d \u201cwill,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks disclosed in the Company\u2019s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.<\/em>\n <\/p>\n


\n
\n \n <\/div>\n

\n
Investor and Media Contact:\r\nGreg Gin\r\nVP, Investor Relations and Corporate Communications\r\nAbeona Therapeutics\r\n+1 (646) 813-4709\r\nggin@abeonatherapeutics.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL\u2122 study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa (RDEB) at UMass Memorial Medical Center in Worcester, MA. The EB-101 pivotal VIITAL\u2122 study is currently ongoing at Stanford University Medical Center in Palo Alto, CA. Target enrollment is 10 to 15 RDEB patients with approximately 35 large, chronic wound sites to be treated in total. Treatment with EB-101 uses gene transfer to deliver a functional COL7A1 gene into a patient\u2019s own skin cells (keratinocytes and its progenitors) and transplanting … <\/p>\n
Continue reading “Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516991","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAbeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL\u2122 study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa (RDEB) at UMass Memorial Medical Center in Worcester, MA. The EB-101 pivotal VIITAL\u2122 study is currently ongoing at Stanford University Medical Center in Palo Alto, CA. Target enrollment is 10 to 15 RDEB patients with approximately 35 large, chronic wound sites to be treated in total. Treatment with EB-101 uses gene transfer to deliver a functional COL7A1 gene into a patient\u2019s own skin cells (keratinocytes and its progenitors) and transplanting … Continue reading "Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-23T11:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa\",\"datePublished\":\"2021-07-23T11:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/\"},\"wordCount\":1154,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/\",\"name\":\"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=\",\"datePublished\":\"2021-07-23T11:33:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/","og_locale":"en_US","og_type":"article","og_title":"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa - Market Newsdesk","og_description":"NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3 VIITAL\u2122 study of its investigational EB-101 treatment for recessive dystrophic epidermolysis bullosa (RDEB) at UMass Memorial Medical Center in Worcester, MA. The EB-101 pivotal VIITAL\u2122 study is currently ongoing at Stanford University Medical Center in Palo Alto, CA. Target enrollment is 10 to 15 RDEB patients with approximately 35 large, chronic wound sites to be treated in total. Treatment with EB-101 uses gene transfer to deliver a functional COL7A1 gene into a patient\u2019s own skin cells (keratinocytes and its progenitors) and transplanting … Continue reading \"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-23T11:33:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa","datePublished":"2021-07-23T11:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/"},"wordCount":1154,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/","name":"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=","datePublished":"2021-07-23T11:33:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTU3NSM0MzExMzg4IzIwMTk3ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abeona-therapeutics-activates-second-clinical-trial-site-in-eb-101-pivotal-phase-3-viital-study-for-recessive-dystrophic-epidermolysis-bullosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL\u2122 Study for Recessive Dystrophic Epidermolysis Bullosa"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516991"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516991\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}